Results of Annual General Meeting held on 2018年5月18日

监管新闻服务

2018年5月18日17:30英国夏令时
 

澳门葡京网赌游戏 announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 1 – 8 were passed as ordinary resolutions and resolutions 9 – 13 were passed as special resolutions.

 

决议

投票支持

投票百分比

投票反对

投票百分比

投票总数

TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL

票保留

1

To receive the Company’s Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2017

 

975,352,556

99.97

286,020

0.03

975,638,576

77.03%

2,190,628

2

确认股利

 

973,207,907

99.66

3,276,414

0.34

976,484,321

77.09%

1,345,238

3

To reappoint PricewaterhouseCoopers LLP as Auditor

 

975,991,837

99.92

823,912

0.08

976,815,749

77.12%

1,010,316

4

To authorise the Directors to agree the remuneration of the Auditor

 

975,217,035

99.83

1,642,984

0.17

976,860,019

77.12%

966,821

5a

To re-elect Leif Johansson as a Director

 

965,159,252

98.78

11,893,311

1.22

977,052,563

77.14%

777,040

5b

To re-elect Pascal Soriot as a Director

 

976,561,635

99.96

423,451

0.04

976,985,086

77.13%

840,934

5c

To re-elect Marc Dunoyer as a Director

 

966,288,665

98.93

10,404,129

1.07

976,692,794

77.11%

1,131,405

5d

To re-elect Geneviève Berger as a Director

 

969,536,507

99.27

7,178,145

0.73

976,714,652

77.11%

1,111,156

5e

To re-elect Philip Broadley as a Director

 

976,367,428

99.97

321,290

0.03

976,688,718

77.11%

1,137,091

5f

To re-elect Graham Chipchase as a Director

 

881,989,499

92.80

68,391,901

7.20

950,381,400

75.03%

27,446,864

5g

To elect Deborah DiSanzo as a Director

 

976,385,364

99.97

318,846

0.03

976,704,210

77.11%

1,122,657

5h

To re-elect Rudy Markham as a Director

 

963,170,539

98.61

13,530,376

1.39

976,700,915

77.11%

1,129,638

5i

To elect Sheri McCoy as a Director

 

976,377,268

99.97

302,558

0.03

976,679,826

77.11%

1,148,061

5j

To elect Nazneen Rahman as a Director

 

975,580,506

99.89

1,085,775

0.11

976,666,281

77.11%

1,161,656

5k

To re-elect Shriti Vadera as a Director

 

974,721,822

99.80

1,938,806

0.20

976,660,628

77.11%

1,168,365

5l

To re-elect Marcus Wallenberg as a Director

 

728,805,452

77.48

211,832,691

22.52

940,638,143

74.26%

37,189,833

6

To approve the Annual Report on Remuneration for the year ended 31 December 2017

 

616,320,491

65.08

330,706,327

34.92

947,026,818

74.77%

30,798,857

7

To authorise limited political donations

 

951,435,712

97.85

20,941,516

2.15

972,377,228

76.77%

5,450,018

8

To authorise the Directors to allot shares

 

879,235,003

90.02

97,511,636

9.98

976,746,639

77.11%

1,081,345

9

To authorise the Directors to disapply pre-emption rights

 

964,350,714

98.99

9,859,917

1.01

974,210,631

76.91%

3,617,671

10

To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments

 

948,470,583

97.36

25,722,825

2.64

974,193,408

76.91%

3,633,732

11

To authorise the Company to purchase its own shares

 

964,157,201

98.76

12,138,730

1.24

976,295,931

77.08%

1,532,147

12

To reduce the notice period for general meetings

 

887,046,924

91.22

85,341,411

8.78

972,388,335

76.77%

5,438,953

13

To adopt new 文章 of Association

962,268,146

99.00

9,709,546

1.00

971,977,692

76.74%

5,848,152

AstraZeneca is pleased to have received shareholder support for all resolutions proposed at the AGM, but is disappointed with the lower level of support received for its Annual Report on Remuneration for the year ended 31 December 2017.

AstraZeneca engaged with its major shareholders during 2017 and is disappointed that enhancements made to Remuneration Report disclosures and changes to the operation of the annual bonus scheme in response to shareholder feedback have not significantly improved the voting result.

The Remuneration Committee has already engaged with a number of shareholders to understand the reasoning behind their decisions not to support the Remuneration Report and will continue to engage with shareholders during 2018 to determine how best to address their concerns.

已发行的股本

截至2018年5月16日, the number of issued shares of the Company was 1,266,635,735股普通股, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company’s 文章 of Association, on a poll every member present in person or by proxy has one vote for every share held.

关于澳门葡京网赌游戏

澳门葡京网赌游戏是一家全球性的, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - 肿瘤学, 心血管, 肾 & 代谢与呼吸. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.澳门葡京网赌游戏.com and follow us on 推特 @AstraZeneca.

 

联系人

媒体关系

 

 

 

 

冈萨洛比

英国/全球

+44 203 749 5916

凯伦伯明翰

英国/全球

+44 203 749 5634

Rob Skelding

英国/全球

+44 203 749 5821

马特·肯特

英国/全球

+44 203 749 5906

雅各布·隆德

瑞典

+46 8 553 260 20

米歇尔Meixell

US

+1 302 885 2677

 

 

 

投资者关系

 

 

托马斯·库德斯克·拉森

 

+44 203 749 5712

克雷格标志

金融,固定收益,硕士&A

+44 7881 615 764

亨利·惠勒

肿瘤学

+44 203 749 5797

米切尔陈

肿瘤学; Other

+1 240 477 3771

Christer Gruvris

Brilinta; Diabetes

+44 203 749 5711

尼克的石头

呼吸; 肾

+44 203 749 5716

澳门葡京赌博游戏免费

 

+1 866 381 7277

艾德里安·坎普
公司秘书
澳门葡京网赌游戏
 

tags

  • 监管